EFFECT OF CYP2E1 INDUCTION BY ETHANOL ON THE IMMUNOTOXICITY AND GENOTOXICITY OF EXTENDED LOW-LEVEL BENZENE EXPOSURE

Autor: Davis H. Daiker, Jonathan B. Ward, Shipp Bk, Schoenfeld Ha, Mary Treinen Moslen, Gisela Witz, Klimpel Gr

Publikováno v: Journal of Toxicology and Environmental Health, Part A. 59:181-196

Potential additive effects of ethanol consumption, a common life-style factor, and low-level benzene exposure, a ubiquitous environmental pollutant, were investigated. Ethanol is a potent inducer of the cytochrome P-450 2E1 (CYP2E1) enzyme, which bio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28a375bf6242dff49525372af8ee1588
https://doi.org/10.1080/009841000156961

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Issues and approaches for ensuring effective communication on acceptable daily exposure (ADE) values applied to pharmaceutical cleaning.

Autor: Olson MJ; SafeBridge Consultants, Inc., USA. Electronic address: michael.olson@safebridge.com., Faria EC; Janssen Pharmaceutical Company, An Affiliate of Johnson & Johnson, USA., Hayes EP; EPHayes Toxicology Services, USA., Jolly RA; Eli Lilly and Company, USA., Barle EL; Novartis, Switzerland., Molnar LR; Mylan, USA., Naumann BD; Merck & Co., Inc., USA., Pecquet AM; University of Cincinnati, USA., Shipp BK; Pfizer Inc., USA., Sussman RG; SafeBridge Consultants, Inc., USA., Weideman PA; Genentech, Inc., USA.

Publikováno v: Regulatory toxicology and pharmacology : RTP [Regul Toxicol Pharmacol] 2016 Aug; Vol. 79 Suppl 1, pp. S19-27. Date of Electronic Publication: 2016 May 24.

A harmonization effort for acceptable daily exposure application to pharmaceutical manufacturing - Operational considerations.

Autor: Hayes EP; EPHayes Toxicology Services, USA., Jolly RA; Eli Lilly and Company, USA. Electronic address: jolly_robert_a@lilly.com., Faria EC; Johnson & Johnson, USA., Barle EL; Novartis, Switzerland., Bercu JP; Gilead Inc., USA., Molnar LR; Mylan, USA., Naumann BD; Merck & Co., Inc., USA., Olson MJ; SafeBridge Consultants, Inc., USA., Pecquet AM; University of Cincinnati, USA., Sandhu R; Safedose Ltd., USA., Shipp BK; Pfizer Inc., USA., Sussman RG; SafeBridge Consultants, Inc., USA., Weideman PA; Genentech, Inc., USA.

Publikováno v: Regulatory toxicology and pharmacology : RTP [Regul Toxicol Pharmacol] 2016 Aug; Vol. 79 Suppl 1, pp. S39-47. Date of Electronic Publication: 2016 Jun 03.